Third Quarter Revenue and Core Growth
Q3 revenue of $211.2 million with core revenue growth of +0.1% year-over-year; demonstrates stability in a mixed market environment.
Food Safety Segment Strength
Food Safety revenue of $156.7 million, delivering 4% core growth year-over-year; led by indicator testing (+11%) and strong pathogen test kit performance.
Improved Profitability Metrics
Adjusted EBITDA of $48.2 million with a margin of 22.8%, an improvement of ~110 basis points sequentially; adjusted gross margin of 51.7% and reported gross margin of 46.9% (essentially flat year-over-year excluding one-time costs).
Positive Free Cash Flow and Balance Sheet Actions
Free cash flow in Q3 was $11.1 million and free cash flow is positive year-to-date; announced sale of genomics business for $160 million (expected net proceeds ~$140M) to reduce debt and target net debt/adjusted EBITDA below 3x by end of 2026.
Petrifilm Manufacturing Transition Progress
On-schedule transition with full validation completed for 100% of production equipment and SKU validations underway; in-house manufacturing expected to improve contribution margin on incremental Petrifilm revenue and enable custom SKUs and R&D prototyping (research-scale R&D line funded Q4 FY26).
Cost Discipline and Operating Expense Improvement
Adjusted operating expenses declined ~9% sequentially versus Q2, driven by cost control and restructuring actions; company emphasizing further OpEx scrutiny and investments targeted at value-creating transformation.
Strategic Transformation Initiatives
Clear transformation plan: (1) commercial prowess (new global commercial leadership and solutions-based selling), (2) high-impact innovation (organic and licensed tech, Petrifilm SKU expansion), and (3) operational efficiency (S&OP, AI-enabled planning, supplier controls).
Market Dynamics Supporting Long-Term Demand
Industry recall activity rose ~15% from 2024 to 2025 and FDA recalled volume more than doubled year-over-year, reinforcing structural demand for reliable food-safety solutions and Neogen's market relevance.